Idiopathic Pulmonary Fibrosis (IPF)

What idiopathic pulmonary fibrosis is

Idiopathic pulmonary fibrosis, or IPF, is a specific, chronic, progressive lung disease in which scar tissue gradually builds up in the lungs for reasons that are not fully understood (“idiopathic” means the cause is unknown). In IPF, that scarring follows a particular, recognizable pattern called usual interstitial pneumonia, or UIP, visible on imaging and, when tissue sampling is needed, on pathology.

It helps to see what this scarring does functionally, compared with healthy lung tissue.

Healthy Lung vs. Fibrotic (IPF) Lung

Healthy Lung vs. Fibrotic (IPF) Lung

Dimension	Healthy Lung Tissue	Fibrotic (IPF) Lung Tissue
Texture	Soft, elastic, able to expand fully with each breath	Thicker and stiffer, similar to how a scar on skin is firmer than the surrounding skin
Air Sac (Alveoli) Walls	Very thin, allowing oxygen to pass easily into the bloodstream	Thickened, making it harder for oxygen to cross into the blood
Lung Volume	Expands to its normal capacity	Cannot expand to its normal volume, producing a restrictive pattern on breathing tests
Gas Exchange	Efficient oxygen transfer	Often reduced, reflected in measurements such as DLCO
Breathing Effort	Normal effort to move a breath in and out	The lungs must work harder to move air, tending to worsen as more tissue becomes involved

IPF is a specific subtype, not a synonym for ILD

This distinction matters enough to state plainly and repeat: IPF is one particular, well-defined subtype of interstitial lung disease (ILD), not another name for the broader category. The comparison below outlines the key differences.

IPF vs. Interstitial Lung Disease (ILD)

IPF vs. Interstitial Lung Disease (ILD)

Dimension	Idiopathic Pulmonary Fibrosis (IPF)	Interstitial Lung Disease (ILD), Broadly
Scope	One particular, well-defined subtype	An umbrella term for well over 200 different conditions involving inflammation, scarring, or both in the interstitium
Cause	No identifiable external cause, by definition	Includes forms with known causes, such as autoimmune conditions, occupational or environmental triggers, and medications, alongside other idiopathic forms
Scarring Pattern	Defined by the specific usual interstitial pneumonia (UIP) pattern	Patterns vary by the specific ILD subtype involved
Typical Course	Generally progressive	Varies considerably; some forms are more treatable or reversible than IPF
Examples	IPF itself	Connective-tissue-disease-associated ILD, exposure-related ILD, medication-related ILD, other idiopathic interstitial pneumonias, and additional less common forms

Because IPF is one of the more studied and consequential forms of ILD, it is sometimes used loosely as a stand-in for the whole category, though two people each told they have “pulmonary fibrosis” or “ILD” may have quite different conditions. See the dedicated interstitial lung disease page for the fuller picture of how ILD is organized and treated; this page focuses specifically on IPF.

Who develops IPF

IPF typically affects older adults, most often in their 60s and 70s, and is diagnosed more often in men, frequently though not always with a history of smoking. When pulmonary fibrosis appears in someone younger, generally under 50, clinicians look more closely for other explanations, including a familial or genetic form of pulmonary fibrosis or an alternative ILD subtype.

Symptoms

The symptoms of IPF are often subtle at onset and develop gradually, which is a major reason diagnosis is frequently delayed by months or longer after symptoms first begin.

Progressive exertional breathlessness is the most common presenting symptom. It typically appears first during physical activity, such as climbing stairs, walking uphill, or other exertion, and is easy to attribute early on to aging, being out of shape, or another minor cause. Over time, breathlessness tends to occur with less and less exertion.

A persistent dry cough is the other hallmark symptom. It is usually non-productive, meaning it does not bring up mucus, and it lingers for weeks to months without an obvious explanation such as a recent respiratory infection.

On physical examination, two findings are classically associated with IPF, though neither is unique to it. Fine, dry crackling sounds heard at the base of the lungs, often described as “Velcro-like,” are common as the disease progresses. Digital clubbing, a painless rounding of the fingertips and nail beds, is also seen in many patients, and fatigue or unintentional weight loss can accompany more established disease.

How IPF is diagnosed

Diagnosing IPF is a structured process, because the disease is defined partly by what is present (the UIP scarring pattern) and partly by what is absent (any other identifiable cause of that scarring). The pathway below outlines how that process typically unfolds.

The Diagnostic Pathway

1. 01→High-Resolution CT (HRCT)Detailed, thin-slice chest imaging identifies a UIP pattern, typically scarring concentrated in the lower and outer lungs and, in more advanced disease, a honeycomb-like appearance where normal architecture is replaced by small cystic spaces. A clearly classic pattern, combined with a history that does not point to another known cause, can support a confident diagnosis without further tissue sampling.↓
2. 02Excluding Other CausesBecause IPF is by definition idiopathic, the process systematically rules out other conditions that can produce a similar scarring pattern, including autoimmune and connective tissue disease, occupational or environmental exposures, certain medications, and other forms of ILD, typically through a detailed history, physical exam, and often targeted blood testing.↓
3. 03→Multidisciplinary Discussion (MDD)When the HRCT pattern is not clearly classic or the overall picture is ambiguous, a coordinated discussion among pulmonology, radiology, and pathology is the recognized standard, improving diagnostic accuracy and agreement compared with any single specialist reviewing the case alone.↓
4. 04Surgical Lung Biopsy, When NeededTissue sampling is not needed in every case. It is generally reserved for situations that remain genuinely indeterminate after imaging, history, and multidisciplinary discussion, since biopsy is invasive and its risks and benefits need to be weighed carefully, particularly in an often older population with reduced lung function.

Pulmonary function testing. Breathing tests in IPF typically show a restrictive pattern, meaning measured lung volumes are reduced because the stiffened, fibrotic lung tissue cannot expand to a normal capacity. This supports the diagnosis and serves as a baseline to track the disease over time.

DLCO. Diffusion capacity for carbon monoxide, or DLCO, estimates how efficiently oxygen crosses from the air sacs into the bloodstream. DLCO is characteristically reduced in IPF and is one of the more important markers used to monitor severity and detect progression at subsequent visits.

Disease course

IPF’s course, summarized above, is generally progressive but genuinely individual. Rather than relying on generic statistics, a physician who has reviewed a specific patient’s imaging, pulmonary function trends, and overall clinical picture is in the best position to discuss what that individual’s course may look like and how it may be expected to evolve.

Treatment

There is no cure for IPF, and no available treatment reverses scarring that has already occurred. Management instead focuses on slowing progression, relieving symptoms, and supporting overall function and quality of life.

Antifibrotic medications. Two FDA-approved drug classes work through different mechanisms to slow the rate lung scarring progresses. They are not a cure and do not reverse existing fibrosis; their role is reducing the pace of further decline. Whether and when to start therapy is decided individually with a pulmonologist.

Supplemental oxygen. As gas exchange becomes progressively impaired, blood oxygen levels can drop, particularly during exertion and eventually at rest. Oxygen is used when testing confirms a clinically significant drop in saturation, and can meaningfully improve exercise tolerance and comfort.

Pulmonary rehabilitation. A supervised program combining exercise training, breathing technique education, and energy conservation strategies. It does not change the underlying fibrotic process, but it can meaningfully improve exercise capacity, symptom burden, and quality of life.

Management of comorbidities. Gastroesophageal reflux is particularly common in people with IPF and is often actively managed, since reflux and microaspiration are thought by many clinicians to play a role in lung injury, though the exact relationship remains an area of ongoing study. Cardiovascular disease and pulmonary hypertension are also monitored and managed as they arise.

Lung transplant evaluation. For appropriately selected candidates, lung transplantation is the one intervention that can replace severely scarred lung tissue. Evaluation involves a detailed, individualized assessment of overall health, disease severity and trajectory, and it is not an option for every patient; timely referral is generally recommended given how long evaluation and waitlisting can take.

Avoiding lung-toxic exposures. Smoking cessation is recommended for anyone with IPF who currently smokes, and minimizing other lung irritants where possible is also generally advised, since ongoing lung injury from other sources can compound the effects of the underlying fibrotic process.

When to seek evaluation

Evaluation for possible IPF is reasonable for anyone, particularly an older adult, with the unexplained symptoms or exam findings described above. Because IPF is progressive and earlier diagnosis generally allows earlier discussion of antifibrotic therapy and other management options, prompt evaluation, rather than watchful waiting, is generally the more sensible approach.

For patients in the North Dallas-Fort Worth area, the pulmonary team at VitalAir Sleep & Lung Center in Frisco, Texas offers pulmonary function testing, DLCO testing, and evaluation for unexplained shortness of breath or persistent cough, which can be an appropriate starting point when IPF or another form of ILD is a consideration.